**Abstract submission guideline**

All submissions must include the first name, last name, department/ institution and email address of the author best suited to answer questions. Include the name, e-mail address, and institutional affiliation and location for all co-authors. If an author’s name appears on more than one abstract, it must be identical on each abstract. The submitter must also identify the author who will present the abstract, which is limited to one presenter. All abstract should be submitted in English.

**How should my contributions be submitted?**

Please send your abstract as a file format PDF to the e-mail address: [conferencemctw@fno.cz](mailto:conferencemctw@fno.cz)

**How exactly should the submitted contributions be structured?**

Title

Authors

Affiliation

Background

Objective

Material & Methods

Results

Summary & Conclusions

Figures

References

Support & Funding

**Is there a limitation regarding characters?**

The limit for the title is 200 characters including spaces.

The abstract body should have a maximum of 3,600 characters including spaces.

The description text of figures and tables etc., References and Support & Funding are not included in the total of 3,600 characters.

For authors / affiliation, you can use as many characters as are required.

**How many submissions should be allowed per author?**

This is unlimited.

**Should conflicts of interest be queried?**

Yes, if there is a real or perceived conflict of interest pertaining to your abstract or presentation, especially one of personal or departmental financial benefit, please provide this information on this site and assure that all appropriate financial and non-financial relationship disclosures have been made. Announcing the disclosures before the presentation of the abstract.

**Do you provide appropriate templates for the submission?**

You can download the appropriate link to the template on our website.

**Abstract Topics**

Abstract topic is wide and includes all hematological malignancies (basic, applied, translational research as well as clinical report/study).

**Encore Abstracts**

Encore abstracts are permitted, however new data is encouraged.